Como Citar
1.
Opromolla DV. Tratamento das reações hansênicas. Hansen. Int. [Internet]. 30º de junho de 2003 [citado 13º de novembro de 2024];28(1):1-3. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35292
Resumo
.
Referências
1. BECX-BLUEMINK, M.; BERHE, D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with
multidrug therapy; experience in the Leprosy Control Programme of All Africa Leprosy and Rehabilitation Training Centre (ALERT) in
Ethiopia. International Journal of Leprosy, v. 60, n.2, p.173-184, 1992.
2. BROWNE, S. G. B663 – possible anti-inflammatory action in lepromatous leprosy. Leprosy Review, v.36, p.9-11, 1965.
3. CONVIT, J.; SOTO, J. M.; SHESKIN, J. Thalidomide therapy in the lepra reaction. Int. J. Leprosy, v.35, p.446-451, 1967.
4. 10th CONGRESO INTERNACIONAL DE LA LEPRA. Therapeutic Commission. Bergen-Noruega, 13-18 de agosto, Anais, 1973.
5. IYER, C. G. et al. WHO coordinated short term double blind trial with thalidomide on the treatment on the treatment of acute lepra reactions in male lepromatous cases. Bull World Health Org., v.45, p.719-732, 1971.
6. IYER, C. G.; RAMU, G. An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug. Leprosy in India, v. 48, p.690-702, 1976.
7. OPROMOLLA, D.V.A.; LIMA, L.S; MARQUES, M.B. Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme).
Hospital, Rio de Janeiro, v.69, n.4, p.827-44, 1966.
8. PANNIKAR, V. The Return of thalidomide: new uses and renewed concerns. WHO Pharmaceutical Newsletter, n. 2, february, 2003.
p.11-12.
9. PENNA, G. O.; PINHEIRO, A. M. C.; HAJJAR, L. A. Talidomida: mecanismo de ação, efeitos colaterais e uso terapêutico. An. bras.
Dermatol., v.73, n.6, p.501-514, 1998.
10. RAMANUJAM, K.; IYER, C.G.; RAMU, G. Open trial with clofazimine in the management of recurrent lepra reaction anf of sulphone sensitive cases: a preliminary report. Leprosy Review, v. 46(supplement), p.117-120, 1975.
11. SHESKIN, J. Further observation with thalidomide in lepra reactions. Leprosy Rev., v.36, n.4, p.183-7, 1965.
12. SHESKIN, J.; CONVIT, J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int. J. Leprosy, v.37, n.2, p.135-46, 1969.
13. SHESKIN, J. Recent experience with thalidomide in Hansen’s disease. Int. J. Dermatol., v.9, n.1, p.56-8, 1970.
14. WATERS, M. F. R. Transactions of the Ninth International Leprosy Congress. International Journal of Leprosy, v.36, p.560-561, 1968.
15. WILLCOX, M. L. The impact of multidrug therapy on leprosy disabilities. Leprosy Review, v. 68, p.350-366, 1997.
multidrug therapy; experience in the Leprosy Control Programme of All Africa Leprosy and Rehabilitation Training Centre (ALERT) in
Ethiopia. International Journal of Leprosy, v. 60, n.2, p.173-184, 1992.
2. BROWNE, S. G. B663 – possible anti-inflammatory action in lepromatous leprosy. Leprosy Review, v.36, p.9-11, 1965.
3. CONVIT, J.; SOTO, J. M.; SHESKIN, J. Thalidomide therapy in the lepra reaction. Int. J. Leprosy, v.35, p.446-451, 1967.
4. 10th CONGRESO INTERNACIONAL DE LA LEPRA. Therapeutic Commission. Bergen-Noruega, 13-18 de agosto, Anais, 1973.
5. IYER, C. G. et al. WHO coordinated short term double blind trial with thalidomide on the treatment on the treatment of acute lepra reactions in male lepromatous cases. Bull World Health Org., v.45, p.719-732, 1971.
6. IYER, C. G.; RAMU, G. An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug. Leprosy in India, v. 48, p.690-702, 1976.
7. OPROMOLLA, D.V.A.; LIMA, L.S; MARQUES, M.B. Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme).
Hospital, Rio de Janeiro, v.69, n.4, p.827-44, 1966.
8. PANNIKAR, V. The Return of thalidomide: new uses and renewed concerns. WHO Pharmaceutical Newsletter, n. 2, february, 2003.
p.11-12.
9. PENNA, G. O.; PINHEIRO, A. M. C.; HAJJAR, L. A. Talidomida: mecanismo de ação, efeitos colaterais e uso terapêutico. An. bras.
Dermatol., v.73, n.6, p.501-514, 1998.
10. RAMANUJAM, K.; IYER, C.G.; RAMU, G. Open trial with clofazimine in the management of recurrent lepra reaction anf of sulphone sensitive cases: a preliminary report. Leprosy Review, v. 46(supplement), p.117-120, 1975.
11. SHESKIN, J. Further observation with thalidomide in lepra reactions. Leprosy Rev., v.36, n.4, p.183-7, 1965.
12. SHESKIN, J.; CONVIT, J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int. J. Leprosy, v.37, n.2, p.135-46, 1969.
13. SHESKIN, J. Recent experience with thalidomide in Hansen’s disease. Int. J. Dermatol., v.9, n.1, p.56-8, 1970.
14. WATERS, M. F. R. Transactions of the Ninth International Leprosy Congress. International Journal of Leprosy, v.36, p.560-561, 1968.
15. WILLCOX, M. L. The impact of multidrug therapy on leprosy disabilities. Leprosy Review, v. 68, p.350-366, 1997.
Este periódico está licenciado sob uma Creative Commons Attribution 4.0 International License.
Downloads
Não há dados estatísticos.
